GlaxoSmithKline signed a $300 million research and development deal with mail gene profiling company 23andMe, gaining access to four million customers DNA information. Health and ancestry service ...

GlaxoSmithKline is suing Moderna for allegedly using technology patented by GSK in its COVID-19 vaccine. Why it matters: It's ...

It follows a similar lawsuit against Pfizer and BioNTech filed in April in which GSK alleges the companies were in violation ...

Nearly six months after lodging a similar complaint against Pfizer and BioNTech over the partners’ COVID shot Comirnaty, GSK ...

Job cuts at its Centres of Excellence for Drug Discovery (CEDD) in the US, UK and Italy, accompanied by an expansion of research in China, are raising questions about where GlaxoSmithKline (GSK ...

The lawsuit focuses on scientific work that helped clear the path for creating mRNA vaccines to fight the COVID-19 pandemic.

GlaxoSmithKline has filed a lawsuit against Moderna, claiming its mRNA vaccines infringe on GSK's patents. GSK seeks ...

Investors in GSK plc (Symbol: GSK) saw new options begin trading today, for the May 2025 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time ...

GSK has revealed updated results from its phase ... resulted in sustained hepatitis B surface antigen (HBsAg) and HBV DNA loss to below the limits of detection in 9% to 10% of participants with ...

That news concerns a discontinued version of GSK's blockbuster heartburn drug Zantac, which was the focus of a series of lawsuits alleging that its active ingredient caused cancer. GSK announced ...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...